Patient-derived antibody recognizes a unique CD43 epitope expressed on all AML and has antileukemia activity in mice-Reference-Cited by-同舟云学术

Patient-derived antibody recognizes a unique CD43 epitope expressed on all AML and has antileukemia activity in mice

Published:2017-08-18 Issue:19 Volume:1 Page:1551-1564
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Gillissen Marijn A.¹²,de Jong Greta¹²,Kedde Martijn¹,Yasuda Etsuko¹,Levie Sophie E.¹,Moiset Gemma¹,Hensbergen Paul J.³,Bakker Arjen Q.¹,Wagner Koen¹,Villaudy Jullien¹,van Helden Pauline M.¹,Spits Hergen¹⁴,Hazenberg Mette D.²⁴

Affiliation:

1. AIMM Therapeutics, Amsterdam, The Netherlands;

2. Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands;

3. Center for Proteomics and Metabolomics, University Medical Center, Leiden, The Netherlands; and

4. Department of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands

Abstract

Key Points AT1413 is a monoclonal antibody isolated from a cured patient with AML that recognizes CD43s, a novel epitope expressed by AML and MDS blasts. AT1413 eliminates CD43s-expressing leukemic blasts in vitro and in vivo and may have potential as a therapeutic antibody.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/1/19/1551/877959/advances008342.pdf

Reference40 articles.

1. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts;Weiden;N Engl J Med,1979

2. Acute myeloid leukaemia in adults;Ferrara;Lancet,2013

3. Graft-versus-leukemia reactions after bone marrow transplantation;Horowitz;Blood,1990

4. Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years;Kantarjian;Cancer,2008

5. Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study;Shah;Br J Haematol,2013

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Apoptosis-mediated ADAM10 activation removes a mucin barrier promoting T cell efferocytosis;Nature Communications;2024-01-15

2. Apoptosis-mediated ADAM10 activation removes a mucin barrier promoting T cell efferocytosis;2023-08-23

3. Autoantibodies to Interferons in Infectious Diseases;Viruses;2023-05-22

4. The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML;Blood Advances;2023-03-31

5. CD43 is an adverse prognostic factor in newly diagnosed multiple myeloma;Leukemia & Lymphoma;2022-07-12